BACKGROUND AND AIMS: Glycoprotein 6 (GP6) is a platelet-specific collagen receptor implicated in the thrombotic pathway to acute myocardial infarction (AMI), but a possible genetic relationship between GP6 and AMI is poorly understood. We tested for the genetic association between AMI and single nucleotide polymorphisms (SNPs) in 24 loci, including GP6. METHODS AND RESULTS: We conducted a case-control study of AMI and GP6 in a community-based population (n = 652 cases, 625 controls). We also examined men and women separately and stratified the latter by use of hormone replacement therapy (HRT). Among both sexes, the strongest association was for a protective missense polymorphism (rs1163662) in the GP6 gene (OR = 0.70; Bonferroni-adjusted p < 0.05). SNPs in GP6 were also strongly associated with AMI among women who reported ever taking HRT, but not among women who never took HRT. Haplotype analyses were consistent with the single-SNP findings. CONCLUSIONS: In this sample of white non-Hispanic men and women, several SNPs in GP6 were significantly related to risk of AMI. Development of pharmacologic therapy directed towards platelet activity and thrombosis may reduce the incidence of AMI among at-risk groups.
BACKGROUND AND AIMS: Glycoprotein 6 (GP6) is a platelet-specific collagen receptor implicated in the thrombotic pathway to acute myocardial infarction (AMI), but a possible genetic relationship between GP6 and AMI is poorly understood. We tested for the genetic association between AMI and single nucleotide polymorphisms (SNPs) in 24 loci, including GP6. METHODS AND RESULTS: We conducted a case-control study of AMI and GP6 in a community-based population (n = 652 cases, 625 controls). We also examined men and women separately and stratified the latter by use of hormone replacement therapy (HRT). Among both sexes, the strongest association was for a protective missense polymorphism (rs1163662) in the GP6 gene (OR = 0.70; Bonferroni-adjusted p < 0.05). SNPs in GP6 were also strongly associated with AMI among women who reported ever taking HRT, but not among women who never took HRT. Haplotype analyses were consistent with the single-SNP findings. CONCLUSIONS: In this sample of white non-Hispanic men and women, several SNPs in GP6 were significantly related to risk of AMI. Development of pharmacologic therapy directed towards platelet activity and thrombosis may reduce the incidence of AMI among at-risk groups.
Authors: Lotta Joutsi-Korhonen; Peter A Smethurst; Angela Rankin; Elaine Gray; Martin IJsseldijk; Catherine M Onley; Nicholas A Watkins; Lorna M Williamson; Alison H Goodall; Philip G de Groot; Richard W Farndale; Willem H Ouwehand Journal: Blood Date: 2003-01-30 Impact factor: 22.113
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Elina Ollikainen; Jussi Mikkelsson; Markus Perola; Antti Penttilä; Pekka J Karhunen Journal: Atherosclerosis Date: 2004-09 Impact factor: 5.162
Authors: Denise Best; Yotis A Senis; Gavin E Jarvis; Helen J Eagleton; David J Roberts; Takashi Saito; Stephanie M Jung; Masaaki Moroi; Paul Harrison; Fiona R Green; Steve P Watson Journal: Blood Date: 2003-06-26 Impact factor: 22.113
Authors: Rehan Qayyum; Diane M Becker; Lisa R Yanek; Nauder Faraday; Dhananjay Vaidya; Rasika Mathias; Brian G Kral; Lewis C Becker Journal: Clin Transl Sci Date: 2014-07-25 Impact factor: 4.689